Antimicrobial Textile Nonwoven Patents: Filing Trends & Gaps 2026
- Filing peaked in 2019 at 12 families, then slid back toward flat activity by the 2022 midpoint — this is a landscape that has already crested, not one still climbing.
- Fibre chemistry outweighs the finished product, D01F filament/fibre claims (37) and A01N biocide claims (29) both outnumber A41D garment claims (11), meaning most protection sits upstream of the fabric itself.
- The most-cited prior art predates the current wave, US6419839B1 on pool and spa filter media carries 147 citations despite sitting outside the mask/apparel use case most recent filers target.
What this landscape covers
This review covers 87 patent families published between 2015 and mid-2026 that combine antimicrobial or antibacterial textile claims with nonwoven or spunbond manufacturing language. The search deliberately pairs a materials term (antimicrobial fibre, antibacterial fabric) with a process term (antimicrobial nonwoven, antibacterial spunbond), so the corpus captures both the active-agent chemistry and the web-forming method rather than either alone. Publication lags filing by roughly 18 months, so the most recent year in any trend line understates real activity.
Filings cluster around fibre and additive chemistry rather than finished apparel, and the receiving-office spread shows the United States, WIPO/PCT and Japan carrying the bulk of formal filing activity, with Europe, India and Australia trailing.
Filing trend and technology composition
Two views of the same 87-family dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
A 2019 peak followed by a flat-to-declining trend
Filings rose to 12 in 2019, the high point of the dataset, then eased back — the 2022 midpoint sits at just 2, and the years since have not recovered to peak levels. This is not a technology in an early growth phase; it is one that had a filing wave and has since gone quiet, at least in what has published so far.
Fibre and biocide chemistry dominate the classification mix
D01F (chemical filament and fibre features) and A01N (biocides/agrochemicals) are the two largest subclasses, ahead of D04H (nonwovens and felts) and D06M (textile chemical treatment). C08K/C08L polymer-additive classes and B01D filtration each carry a meaningful share, while A41D garment claims are the smallest of the eight — most of the protected ground is in how the fibre or finish is made, not in the finished product.
Shares are the percentage of the 87 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Antimicrobial Textile Nonwoven with Eureka
This page is one run against one query. Ask Eureka your own question about antimicrobial textile nonwoven and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Antimicrobial Nonwoven Cloth, Preparation Method Thereof and Mask with the Antimicrobial Nonwoven Cloth
Discloses an antimicrobial nonwoven cloth built from polypropylene combined with sodium p-styrenesulfonate, a silane coupling agent, PHMB (polyhexamethylene biguanidine hydrochloride), a zinc salt, bamboo charcoal fibre and fumed silica, plus a preparation method and a mask application intended to limit bacterial spread through air and saliva.Filed as US20210068479A1, published 2021-03-11.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6419839B1 | Pool and spa filter media | 147 |
| 2 | JP1992194074A | Processing of cloth having antibacterial and deodorizing property | 24 |
| 3 | US20100003296A1 | Manufacturing methods and applications of antimicrobial plant fibers having silver particles | 20 |
| 4 | US20110086078A1 | Fibrous antimicrobial materials, structures, and barrier applications | 18 |
| 5 | US20110250253A1 | Antimicrobial treatment of synthetic nonwoven textiles | 17 |
| 6 | US20210068479A1 | Antimicrobial Nonwoven Cloth, Preparation Method Thereof and Mask with the Antimicrobial Nonwoven Cloth | 15 |
| 7 | US20150275404A1 | Nonwoven Having High Microbial Kill Rate And High Efficacy And Articles And Uses Therefrom | 14 |
| 8 | JP1997217274A | Antimicrobial nonwoven fabric | 14 |
| 9 | JP1988143918A | Nonwoven fabric for air filter | 14 |
| 10 | US12043721B2 | Antiviral/antimicrobial polymer compositions, fibers, and products | 11 |
Citation counts reward older filings simply for having been in circulation longer; read them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three read-throughs from the trend, classification and citation data above.
A wave that has already broken
The dataset's peak year, 2019, has not been matched since; by the 2022 midpoint annual filings had dropped to 2. Combined with the 18-month publication lag, the honest reading is a technology area that saw a burst of filing activity — plausibly tied to a period of heightened demand for antimicrobial protective textiles — and has not sustained it.
Upstream chemistry is the crowded ground
Fibre-feature claims (D01F) and biocide/agrochemical claims (A01N) together account for more filings than the nonwoven-process (D04H) and finish-treatment (D06M) classes combined. Anyone entering this space with a novel active agent or fibre modification is filing into the densest part of the map, not the emptiest.
The most-cited reference sits outside the core use case
The single most-cited record in this corpus is a pool and spa filter media patent, not a mask or apparel filing. Examiners and applicants alike are drawing on filtration-media antimicrobial art as foundational prior art, which matters when scoping a freedom-to-operate search that only looks at apparel-classified filings.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to antimicrobial textile nonwoven, with the prior art for and against each one.
Who is filing, and where the field is open
Recent-year momentum across the tracked assignees is flat: every one of the named assignees shows zero filings in the latest year, and one shows a -100% year-on-year drop. That is consistent with the overall trend line — this is a corpus with an identifiable 2019 wave and little visible recent-year renewal, though the 18-month publication lag means the last one to two years are undercounted.
Filing is largely solo, with a few tight collaboration clusters
Only eight co-assignee pairs appear across the dataset, and the strongest ones repeat the same three individual names across multiple pairings — a small, tightly linked filing group rather than a broad web of joint ventures.
No assignee shows active recent-year filing
Every assignee surfaced in the recent-momentum view, from large chemical and materials companies to individual named inventors, shows zero filings in the most recent tracked year. Read this alongside the publication lag rather than as proof the field has stopped.
Filing activity centres on the US, PCT and Japan
The United States leads as a receiving office, with WIPO/PCT and Japan close behind; Europe, India and Australia each see single-digit-to-low-double-digit filings. A freedom-to-operate check limited to one jurisdiction will miss a meaningful share of the corpus.
| Assignee | Recent year | YoY |
|---|---|---|
| Ascend Performance Materials | 0 | -100% |
| BASF SE | 0 | — |
| Hollingsworth & Vose Company | 0 | — |
| Mitsubishi Gas Chemical Company, Inc. | 0 | — |
| HENDRICKS GUY CARMEN | 0 | — |
| DEISENROTH TED | 0 | — |
| CUNKLE GLEN T | 0 | — |
| Honeywell International Inc. | 0 | — |
Where to take this analysis
The dataset points to a few concrete next steps depending on whether you're scoping freedom-to-operate, deciding where to file, or tracking a competitor.
Run a freedom-to-operate check across the top three receiving offices
With the US, PCT and Japan carrying the bulk of filings, a single-jurisdiction search will understate real risk. Cross-check claims against all three before committing to a formulation or process.
Explore in Patsnap EurekaScope a claim in the under-claimed branches
Antiviral-specific finishes and garment-integrated nonwoven claims (A41D) sit well below the fibre-chemistry claim density. A narrowly drafted claim there faces less crowded prior art.
Explore in Patsnap EurekaTrack whether the 2019 filing wave resumes
Given the publication lag, filings from the last one to two years are still arriving. Re-run this trend in six to twelve months to see whether the flat period was temporary or structural.
Explore in Patsnap EurekaCommon questions on this landscape
This landscape identifies 87 patent families published between 2015 and mid-2026 that combine antimicrobial or antibacterial textile claims with nonwoven or spunbond process language. That count reflects families, which is the fairer unit than raw document counts because it neutralises duplicate filings of the same invention across jurisdictions. The true figure for the most recent one to two years will be higher once publication catches up, since publication typically lags filing by around 18 months.
The dataset shows filing concentrated among a small group of assignees alongside a long tail of single-filing entrants, rather than one dominant player controlling the field. Recent-year momentum data shows every tracked assignee, including several established materials and chemical companies, at zero filings in the latest year — consistent with the broader flat-to-declining trend since the 2019 peak. Anyone assessing competitive position should look at cumulative family counts and co-assignee clusters rather than a single recent year, given the reporting lag.
In this corpus, antimicrobial claims (built around A01N biocide chemistry) are far more numerous than antiviral-specific claims, which appear as a narrower, less-crowded sub-area. Antimicrobial typically covers bacterial and fungal action broadly, often via biocidal agents like silver, zinc salts or PHMB, while antiviral claims require evidence targeting viral particles specifically. The relative scarcity of antiviral-specific filings makes it one of the more open branches for a narrowly drafted new claim.
The United States is the leading receiving office in this dataset with 25 records, followed by WIPO/PCT filings and Japan, with Europe, India and Australia trailing behind. A PCT filing gives the broadest initial coverage and preserves the option to enter the US and Japanese national phases, which together account for the largest share of activity tracked here. The choice should still follow where manufacturing and target markets sit, since office concentration reflects where past applicants filed, not necessarily where future demand will be.
The filing trend in this dataset peaked in 2019 at 12 families and had fallen back to 2 by the 2022 midpoint, with no tracked assignee showing recent-year filing activity. That pattern suggests a wave tied to a specific period of demand rather than sustained steady growth, though the 18-month publication lag means the last one to two years of filings are undercounted and could still show renewed activity once they publish. Anyone deciding whether to file now should weigh the flat recent trend against the still-open sub-areas like antiviral-specific finishes and garment-integrated claims.
Research Antimicrobial Textile Nonwoven in depth with Eureka
Go past this page: query the whole antimicrobial textile nonwoven corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.